Diurnal Group PLC (LSE:DNL) - Share price - Overview

Stock Report

Diurnal Group PLC DNL

Last Price
GBX142.50

Day Change
0.00|0.00%

As of 17/11/2017
14:22:13 GMT | GBX
Minimum 15 Minutes Delay.

Last Close142.50p
Day Range142.00 - 142.00
Mkt Cap74.91Mil
52-Wk Range105.00 - 143.00
Yield %0.00
ISINGB00BDB6Q760
Volume3,634
P/E-7.92
P/SInfinity
P/CF-7.25

Share Price

Total Returns 17/11/2017

 Chg (%)  
More ...
Diurnal Group PLC5.95 
FTSE 100 TR GBP-1.44
 
Financials
201520162017
More ...
Income Statement
Turnover0.000.000.00
Operating Profit-2.73-6.99-12.07
Net Profit-2.69-6.57-9.43
Reported EPS-5.15-15.00-18.00
Balance Sheet
Current Assets6.4530.6423.91
Non Current Assets0.020.010.02
Total Assets6.4630.6523.93
Current Liabilities0.421.483.34
Total Liabilities0.424.726.85
Total Equity6.0425.9317.08
Cash Flow
Operating Cash Flow-2.69-5.55-10.45
Net Change in Cash4.6910.04-7.23
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2018-16.44-25.27--5.64---
2019-15.24-23.25--6.13---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
17/11/2017Sale of Option SharesMartin Whitaker134.7033,65045,327.00
17/11/2017Exercise of OptionMartin Whitaker120.0069,56583,478.00
06/09/2017PurchaseMr. John Goddard5.0010,791540.00
16/01/2017PurchaseAlan Raymond110.009,0009,900.00

Company Profile

Diurnal Group PLC is a specialty pharmaceutical company developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

Sector

Drug Manufacturers - Specialty & Generic

Market Position

996 of 1833 Companies

Index

Outlook

(13/10/2017) ceo - "...the Board believes that the potential for Diurnal looks very positive"

Next Event 21/11/2017

Next AGM
Ratios
CompSecMkt
More ...
PER (E)-5.8213.6316.14
Div Yld (E)0.004.134.26
PEG (E)0.001.241.34
ROCE-57.73180.3415.81
Op Mrgn0.00-8.42-9.53
EPS Grwth0.0012.8214.73
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. Peter Allen
Chief Executive OfficerMartin Whitaker
Chief Financial Officer & Company SecretMr. Richard Bungay
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.